SecBot

SecBot
NYSE· Pharmaceutical Preparations· Inc. IN· CIK 0000059478

LLY

ELI LILLY & Co
$1,257.03 ▲ +0.43%
Prev close $1,251.61
Market cap$1.2T
ConsensusBuy
12-mo target$1,328.05 (+5.7%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (2 insiders)High Impact Filing (8/10)5 New Institutional Positions Biotech & Drug Discovery
Snapshot
The big-picture read on LLY right now — valuation, ownership and activity at a glance.
Market Cap
$1.2T
Cap Size
Mega Cap
Analyst Consensus
Strong Buy (79%)
Inst. Holders
21 funds
Inst. Value
$3.4B
Inst. Activity
5 buys / 1 sells
Insider Activity
$0.00 buy / $34.6M sell
Insider Net $
-$34.6M
Social Sentiment
60° Warm
SEC Reports
14
Press Releases
1
Congressional
16 trades
Price chart 30d +9.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 16, 2026 drug_approval
EMA: Human medicines European public assessment report (EPAR): Foundayo, Orforglipron, Status: Opinion
Human medicines European public assessment report (EPAR): Foundayo, Orforglipron, Status: Opinion
Sep 30, 2026 Inst.
Assenagon Asset Management S.A. — ADD
784,936 shares ($908.2M)
Sep 30, 2026 Inst.
Ninety One UK Ltd — TRIM
344,968 shares ($399.2M)
Sep 23, 2026 Event
ONSWIK
Original Approval — Type 1 - New Molecular Entity — INJECTABLE
Sep 21, 2026 Insider
Alvarez Ralph was granted 10.659 shares
Director @ $1,164.89 ($12.4K)
Sep 21, 2026 Insider
Sulzberger Gabrielle was granted 4.257 shares
Director @ $1,164.89 ($5.0K)
Sep 21, 2026 Insider
Fyrwald J Erik was granted 8.513 shares
Director @ $1,164.89 ($9.9K)
Sep 11, 2026 Press
Eli Lilly completed its acquisition of AtaiBeckley, a clinical-stage biopharma developing neuroplastogens for mental hea
Impact 5/10
Analyst ratings buy % +5.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Buy 79% rate it Buy or better · 38 analysts
Strong Buy 11 29% Buy 19 50% Hold 7 18% Sell 1 3% Strong Sell 0 0%
Recent analyst actions
DateFirmActionRatingFirm rating
Oct 12, 2026RBC CapitalREITERATEOutperform 55%
Oct 8, 2026Cantor FitzgeraldMAINTAINOverweight 49%
Oct 7, 2026Morgan StanleyMAINTAINOverweight 55%
Sep 28, 2026JP MorganMAINTAINOverweight 55%
Sep 22, 2026TD CowenREITERATEBuy 56%
Sep 18, 2026GuggenheimMAINTAINBuy 52%
Sep 10, 2026HSBCMAINTAINReduce 55%
Aug 7, 2026Truist SecuritiesMAINTAINBuy 55%
Aug 6, 2026Wells FargoMAINTAINOverweight 54%
Aug 6, 2026Cantor FitzgeraldMAINTAINOverweight 49%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 2026111971079%
Aug 1, 2026111971079%
Jul 1, 2026111971079%
Jun 1, 2026112071079%
May 1, 2026111981077%
Apr 1, 2026121881077%
Mar 1, 2026121890077%
Feb 1, 20261116100073%
Price targets
Where 30 covering analysts think LLY trades over the next 12 months.
$1,328.05 +5.7% upside Buy
Current$1,257.03 Low$930.00 Median$1,380.50 High$1,600.00 30 analysts
$930.00$1,600.00
Analyst rating Buy· 1.6/5 as of Oct 19, 2026
Social media sentiment mood -20.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
60°
Warm
BearishNeutralBullish
35 mentions 17 bullish 9 bearish 9 neutral
Recent posts
stocks Bearish 5d 11h ago
Changing Universe to avoid Wash Sale Disallowed Losses
▲ 1 · 💬 6· ⚡ 0.5
stocks Neutral 14d 13h ago
LLY 2000 6-12 months
▲ 1 · 💬 0· ⚡ 0.5
options Bullish 18d 10h ago
Started grading my alerts on actual bid/ask instead of mid and wow
▲ 1 · 💬 5· ⚡ 0.5
options Neutral 23d 19h ago
Why did this call option go up when LLY is down?
▲ 1 · 💬 1· ⚡ 0.5
wallstreetbets Neutral 23d 19h ago
Why is call option up when LLY is down?
▲ 1 · 💬 0· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
14 SEC filing reports analyzed · 4 bullish, 1 bearish, 0 mixed, 9 neutral · avg impact 4.1/10.Plus 1 press releases.
NEUTRALCOURT-RULING4/10
Eli Lilly's false advertising lawsuit against Mochi Health and compounding pharmacies survives in pa
Sep 9, 2026
NEUTRALCLUSTER3/10
Two senior executives at Eli Lilly sold a combined $10.01M in stock over the past week, including th
Aug 19, 2026
NEUTRALCLUSTER3/10
Two senior Eli Lilly executives (SVP Finance/CAO and EVP GC/Secretary) sold a combined $8.32M in ope
Aug 12, 2026
NEUTRALCOURT-RULING3/10
The court issued a pretrial order in Nektar Therapeutics v. Eli Lilly & Co, setting a jury trial for
Aug 8, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 16, 2026
Clinical Trial
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
Phase Phase 3 — COMPLETED
Oct 16, 2026
Clinical Trial
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
Phase Phase 3 — COMPLETED
Oct 16, 2026
Clinical Trial
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
Phase Phase 2 — COMPLETED
Oct 16, 2026
drug_approval
EMA: Human medicines European public assessment report (EPAR): Foundayo, Orforglipron, Status: Opinion
Human medicines European public assessment report (EPAR): Foundayo, Orforglipron, Status: Opinion
Oct 16, 2026
short_volume
Short Volume: LLY — 55.3% short (0.6M / 1.0M)
Short: 564,474 | Exempt: 600 | TRF Vol: 1,021,551 | Short Ratio: 55.3% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$7.11$4.65–$10.681.3%-28.0%3↑ 7↓$22.5B18
Next Q$10.10$9.00–$11.4633.9%+1.2%6↑ 4↓$23.5B16
Current FY$35.02$31.33–$38.5644.6%-4.7%5↑ 8↓$88.5B28
Next FY$47.19$40.73–$52.3434.8%-0.3%7↑ 5↓$102.0B26
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$7.108—
7d ago$8.095-0.987
30d ago$9.871-2.763
60d ago$9.871-2.763
90d ago$9.440-2.332
Institutional ownership
Which big funds own LLY (from quarterly 13F filings) and who is adding or trimming.
21 institutional holders with $3.4B total value (2,914,624 shares) as of 2026-Q3. Top holders: Assenagon, Ninety, FJARDE. Net buying activity: 5 institutions added/increased vs 1 reduced.
Top holders — 2026-Q3
FundSharesValue% TrackedLast move
Assenagon Asset Management S.A.784,936$908.2M27.1%ADD +56.7%
Ninety One UK Ltd344,968$399.2M11.9%TRIM -39.5%
FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND255,175$295.3M8.8%—
TD Waterhouse Canada Inc.243,316$280.1M8.4%ADD +26.5%
Czech National Bank229,903$266.0M7.9%—
IFM Investors Pty Ltd189,074$218.8M6.5%—
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC204,606$218.0M6.5%—
Vontobel Holding Ltd.158,885$183.8M5.5%—
CONGRESS ASSET MANAGEMENT CO124,514$144.1M4.3%—
Artemis Investment Management LLP76,310$88.3M2.6%—
Recent position changes
FundActionPrevCurrentChangeValue
Assenagon Asset Management S.A.ADD501,025784,936+56.7%$908.2M
Ninety One UK LtdTRIM570,405344,968-39.5%$399.2M
TD Waterhouse Canada Inc.ADD192,333243,316+26.5%$280.1M
Farther Finance Advisors, LLCADD43,80968,083+55.4%$78.8M
Concurrent Investment Advisors, LLCADD46,83663,892+36.4%$73.9M
MATHER GROUP, LLC.ADD9,13213,156+44.1%$15.2M
NORGES BANKNEW—11,471,413—$13.8B
AMERICAN CENTURY COMPANIES INCADD1,845,9222,354,837+27.6%$2.8B
BARCLAYS PLCTRIM1,563,6251,143,891-26.8%$1.4B
CITADEL ADVISORS LLCDOUBLED241,714945,456+291.1%$1.1B
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
18 insiders, 50 transactions. Net -$34.6M — $0.00 bought, $34.6M sold.
DateInsiderTitleTypeSharesPriceValue
Sep 21, 2026Alvarez RalphDirectorAWARD10.659$1,164.89$12.4K
Sep 21, 2026Sulzberger GabrielleDirectorAWARD4.257$1,164.89$5.0K
Sep 21, 2026Fyrwald J ErikDirectorAWARD8.513$1,164.89$9.9K
Sep 21, 2026LUCIANO JUAN RDirectorAWARD13.664$1,164.89$15.9K
Sep 9, 2026Seymour MelissaEVP, Global QualityGIFT12——
Sep 2, 2026Hernandez EdgardoEVP & Pres., Mfg. OperationsGIFT13——
Sep 2, 2026Dozier EricEVP, Chief People OfficerGIFT216——
Aug 17, 2026Sulzberger GabrielleDirectorAWARD4.191$1,183.16$5.0K
Aug 17, 2026Alvarez RalphDirectorAWARD10.495$1,183.16$12.4K
Aug 17, 2026Fyrwald J ErikDirectorAWARD8.382$1,183.16$9.9K
Congressional trades
LLY trades disclosed by members of Congress, with disclosure delay.
10 members · 8 buys / 8 sells
DateMemberPartyChamberTypeAmountAssetDisclosed
Jul 10, 2026Dan NewhouseRHOUSESELL$1,001 - $15,000Eli Lilly and CoJul 20, 2026(11d)
Jul 1, 2026Michael RulliRHOUSESELL$1,001 - $15,000Eli Lilly and CoAug 10, 2026(41d)
Jun 10, 2026Gilbert CisnerosDHOUSEBUY$50,001 - $100,000Eli Lilly and CoJul 3, 2026(24d)
Jun 2, 2026Ro KhannaDHOUSEBUY$1,001 - $15,000Eli Lilly and CoJul 8, 2026(37d)
Apr 8, 2026Lizzie FletcherDHOUSESELL$1,001 - $15,000Eli Lilly and CoMay 1, 2026(24d)
Apr 2, 2026Byron DonaldsRHOUSEBUY$1,001 - $15,000Eli Lilly and CoMay 14, 2026(43d)
Apr 2, 2026Byron DonaldsRHOUSEBUY$1,001 - $15,000Eli Lilly and CoMay 14, 2026(43d)
Mar 13, 2026Gilbert CisnerosDHOUSESELL$1,001 - $15,000Eli Lilly and CoApr 8, 2026(27d)
Feb 26, 2026David TaylorRHOUSEBUY$1,001 - $15,000Eli Lilly and CoMar 9, 2026(12d)
Feb 13, 2026Angus KingOSENATESELL$1,001 - $15,000Eli Lilly and CoMar 24, 2026(39d)
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for LLY.
Shares short
7,035,434
Settlement Sep 30, 2026
Change vs prior
-6.4%
Semi-monthly cycle
Days to cover
2.9
At avg daily volume
Of shares outstanding
≈0.8%
Estimate — not % of float
All LLY filing & press-release reports (15)